About
Drugs Based on Recombinant DNA Technology, BBB-crossing antibodies
Areas of Focus
Categories
BiosimilarsBiologics & BiopharmaceuticalStem Cell & Cellular TherapyAntibodyJapan
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
14
As Collaborator
2
Total Enrollment
739
By Phase
PHASE1/PHASE2: 5PHASE3: 4PHASE2/PHASE3: 2PHASE2: 5
By Status
COMPLETED: 7ACTIVE_NOT_RECRUITING: 4UNKNOWN: 3RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06488924Lead Sponsor
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
PHASE1/PHASE2Recruiting
10 participants
Started: Nov 5, 2024 · Completed: Apr 30, 2030
NCT06095388Lead Sponsor
Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
PHASE1/PHASE2Active, not recruiting
15 participants
Started: Oct 4, 2023 · Completed: Oct 31, 2029
NCT05594992Lead Sponsor
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
PHASE3Enrolling by invitation
80 participants
Started: Feb 22, 2023 · Completed: Feb 28, 2028
NCT04573023Lead Sponsor
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
PHASE3Active, not recruiting
86 participants
Started: Feb 14, 2022 · Completed: Oct 31, 2027
NCT04453085Lead Sponsor
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)
PHASE1/PHASE2Completed
14 participants
Started: Oct 28, 2021 · Completed: May 2, 2025
Locations (1)
Headquarters
Hyogo, Japan
Map
Loading map...